Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT06122389
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06123494
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 660
- Registration Number
- NCT06099990
Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06093945
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06091748
A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06086912
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
Drug-Drug Interaction Study Between Henagliflozin Proline and Hydrochlorothiazide
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06083116
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06062355
Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06062680
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 864
- Registration Number
- NCT06057610
© Copyright 2024. All Rights Reserved by MedPath